Results 41 to 50 of about 265 (112)

Silencing the System: A Scoping Review of RNA-Interference Therapeutics and Gene-Targeting Strategies in Hypertension Management

Hypertension remains a leading global driver of cardiovascular morbidity and mortality, and a major barrier to blood pressure control is poor adherence to daily oral antihypertensive regimens.
Sidra Saif
core   +1 more source

Reimagining Blood Pressure Management: The Role of Zilebesiran in Targeting Angiotensinogen

Hypertension remains a major global health burden and a leading risk factor for cardiovascular morbidity and mortality. Despite the availability of multiple antihypertensive therapies, a significant proportion of patients fail to achieve optimal BP control due to limited efficacy, side effects, or poor adherence.
openaire   +1 more source

Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Eur J Clin Pharmacol
Hussain M, Hassan M, Sohaib A, Ahmed T, Khan S, Hannan A, Dhedhi HAA, Naz A, Cheema AH, Ahmed F.   +9 more
europepmc   +1 more source

RNA therapeutics: A promising therapy for future cardiology. [PDF]

J Cardiovasc Thorac Res
Ghaffari S, Entezari-Maleki T.
europepmc   +1 more source

Targeting Angiotensinogen With N-Acetylgalactosamine-Conjugated Small Interfering RNA to Reduce Blood Pressure. [PDF]

Arterioscler Thromb Vasc Biol, 2023
Ye D, Cruz-López EO, Tu HC, Zlatev I, Danser AHJ.   +4 more
europepmc   +1 more source

Special Issue: Recent Research on Hypertension and Related Complications. [PDF]

Int J Mol Sci
Delrue C, Speeckaert MM.
europepmc   +1 more source

The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board. [PDF]

Clin Kidney J
Kanbay M, Copur S, Capasso G, Turkmen K, Delanaye P, Bruchfeld A, Abd ElHafeez S, Ferro CJ, Verhaar MC, Pesce F, Liakopoulos V, Boor P, Adamczak M, Vivarelli M, Navarro-González JF, Kramann R, Florquin S, Valdieso JM.   +17 more
europepmc   +1 more source

From daily burden to scheduled protection: the "vaccine-like" shift in hypertension. [PDF]

J Hum Hypertens
Corrêa LMA, Mazur GR, Santiago CBG, Barbosa AA, Brandão LKV, de Santana GC, Dante LE.   +6 more
europepmc   +1 more source

Zilebesiran: A Paradigm Shift in Hypertension Management Through Biannual RNA Interference Therapy- A Literature Review

Hypertension is the most prevalent modifiable contributor to cardiovascular disease and mortality worldwide; nevertheless, achieving consistent blood pressure control in real-world settings remains a challenge despite the availability of multiple antihypertensive agents.
openaire   +2 more sources

Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules. [PDF]

Clin Pharmacokinet
Badri P, Kolachana K, Duong A, Lasko M, Nandi T, Mehrotra N, Robbie GJ.   +6 more
europepmc   +1 more source